Dabigatran 110 Mg & 150 Mg

Dabigatran: Uses, Benefits, Dosage, and Safety Overview

Dabigatran etexilate is an oral anticoagulant (blood thinner) used to help prevent harmful blood clots. It belongs to the class of direct thrombin inhibitors, which work by blocking thrombin—an enzyme essential for clot formation. By reducing the body’s ability to form clots, Dabigatran helps lower the risk of stroke, systemic embolism, and venous thromboembolism (VTE).

Indications

Dabigatran is commonly prescribed for:

• Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF).

• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

• Prevention of recurrent DVT or PE after completing initial therapy.

• Post-operative thromboprophylaxis following hip replacement surgery (in some regions).

Dosage

Dabigatran is typically available in 75 mg, 110 mg, and 150 mg capsules.
Common regimens include:

• 150 mg twice daily for most adults with non-valvular AF.

• 110 mg twice daily may be used in older adults or those with higher bleeding risk.

• For DVT/PE treatment, the typical dose is 150 mg twice daily following 5–10 days of initial parenteral anticoagulation.

• Dose adjustments depend on kidney function, age, and concomitant medications.

Capsules must be swallowed whole. Opening or crushing them increases absorption and bleeding risk.

Overdose & Bleeding Risk

Overdose or excessive exposure can lead to serious bleeding, including gastrointestinal or internal bleeding. Symptoms may include prolonged bruising, blood in stool or urine, coughing up blood, dizziness, or unexpected weakness.

A key advantage of Dabigatran is the availability of a specific reversal agent, idarucizumab, used in emergency situations to rapidly neutralize its anticoagulant effect.

Precautions

Individuals with severe kidney impairment, active bleeding, or recent major surgery may not be suitable candidates. Interactions with antiplatelets, NSAIDs, or other anticoagulants can increase bleeding risk.